Dexcom 3Q 2026: Revenue $1.34B, Net income $275.1M, EPS $0.72— 10-Q Summary
Dexcom reported Q3 2026 revenue of $1.34B, up 11.2% YoY, with net income of $275.1M, down 3.1%, and EPS of $0.72, up 2.9%. Distributor and direct revenue both increased. The company received FDA clearance for Stelo and plans to scale manufacturing and invest in product development.
How this was made
The 30-second read
Why it matters
Revenue growth plus Stelo’s FDA clearance for children aged 2+ can improve the demand outlook and product adoption curve, while the net income decline flags potential cost or tax effects that may matter for valuation.
Market read
Traders can update near-term expectations using the quarter’s reported revenue/EPS and the incremental regulatory catalyst for Stelo’s pediatric market.
What to watch
The summary highlights gross margin drivers but does not quantify guidance, cash flow, or expense trends; traders may need the full 10-Q to assess sustainability of manufacturing efficiency and mix improvements.
Background
The piece is a brief summary of Dexcom’s filed 10-Q for 3Q 2026, including financial metrics and product/regulatory updates.
Ticker impact
Dexcom’s 3Q 2026 10-Q reports $1.34B revenue (+11.2% YoY) and diluted EPS of $0.72, plus Stelo FDA clearance for children aged 2+.
Likely upward bias as traders price in growth from distributor/direct mix and incremental Stelo adoption, offset by the net income dip.
The article provides fresh quarterly financial datapoints and a specific FDA clearance event, both of which can shift near-term expectations for revenue mix and product uptake.
Market effects
CGM peers may see read-across interest as Stelo’s pediatric clearance can expand the addressable market narrative for non-insulin users.
Limited direct regional spillover; FDA clearance is US-specific but can influence global sentiment for diabetes tech.
Moderate, mainly through investor sentiment toward diabetes monitoring device adoption and reimbursement expectations.
Counterpoint
Net income fell 3.1% even as EPS rose, suggesting margin or cost pressures that could cap upside if they persist.
Key entities
- companyDexcom Inc
US-listed CGM and biosensor company reporting 3Q 2026 revenue, net income, EPS, and Stelo FDA clearance details in its 10-Q.
- productStelo
Dexcom’s over-the-counter biosensor, cleared by the FDA in June 2026 for children aged 2 and older who do not use insulin.
